Blog Posts - Side Effect: Cardiovascular (heart Attack, Stroke, Heart Failure, Pe, Dvt)



Bayer's Corporate Reports About Their YAZ / Yasmin Settlement Program Show Progress Continues To Be Made, Albeit At A Slow Pace

First Lawsuits In The YAZ / Yasmin / Gianvi / Ocella / Beyaz / Safyral Drug Injury Litigation Were Filed In 2009, With Thousands Of Cases Still Pending (Posted by Tom Lamb at DrugInjuryWatch.com) The most recent Bayer information about the YAZ / Yasm...
by Drug Injury Watch on Oct 19, 2015

In The Shadow Of Recent Announcement About Diabetes Drug Jardiance Medical Study Results There Lingers Safety Concerns For SGLT-2 Inhibitors

As With Invokana and Farxiga, Jardiance Is Subject Of Several Drug Regulatory Agency Investigations About Ketoacidosis And Other Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) Jardiance is part of the Sodium-Glucose Co-Transporter-2 (SGLT-2...
by Drug Injury Watch on Aug 21, 2015

Will There Be Another Drug Label Change For YAZ And Other Drospirenone (DRSP) Birth Control Pills, As FDA Required For Ortho Evra Years Ago

Since Bayer Revised YAZ Label In April 2012 There Has Been More Medical Evidence That DRSP Pills Increase Risks Of Blood Clot Side Effects Like DVT And PE (Posted by Tom Lamb at DrugInjuryWatch.com) The drug labels for Yasmin, YAZ, Safyral, and Beyaz...
by Drug Injury Watch on Jul 29, 2015

Onglyza Update: FDA May Require A New Warning About Possible Increased Risk Of Heart Failure For Diabetes Drugs Onglyza And Kombiglyze XR

April 2015 FDA Advisory Committee Voted For An Onglyza Drug Label Change About Side Effects Risks, With One Panelist Voting Of An Onglyza Recall (Posted by Tom Lamb at DrugInjuryWatch.com) As previewed in our March 2015 article, "Cardiovascular...
by Drug Injury Watch on Jul 23, 2015

Onglyza Update: FDA May Require A New Warning About Possible Increased Risk Of Heart Failure For Diabetes Drugs Onglyza Or Kombiglyze XR

April 2015 FDA Advisory Committee Voted For An Onglyza Drug Label Change About Side Effects Risks, With One Panelist Voting Of An Onglyza Recall (Posted by Tom Lamb at DrugInjuryWatch.com) As previewed in our March 2015 article, "Cardiovascular...
by Drug Injury Watch on Jul 23, 2015

Invokana Lawsuits Are Expected To Be Filed While FDA And Other Drug Regulators Investigate Side Effects Reports

Drug Injury Lawyers Also See Possible Farxiga And Jardiance Cases For Patients Who Have Ketoacidosis, Kidney Failure, Stroke, Or Heart Attack (Posted by Tom Lamb at DrugInjuryWatch.com) With there being a growing number of Type 2 diabetes patients in...
by Drug Injury Watch on Jul 2, 2015

Farxiga / Jardiance / Invokana Safety As Regards Diabetic Ketoacidosis Now Being Studied By Health Canada In Addition To Current FDA Investigation

Institute For Safe Medication Practices Signal For Invokana Kidney Failure Risks Seems To Apply To Farxiga, Jardiance, And Other SGLT2 Diabetes Drugs Also (Posted by Tom Lamb at DrugInjuryWatch.com) On May 15, 2015 the FDA announced it is investigati...
by Drug Injury Watch on Jun 25, 2015

According To Bayer, In April 2015 There Were 400 Fewer YAZ / Yasmin Lawsuits Pending, 100 More Settlements, And 500 Cases Just Seem To Vanish From Their Radar

Now About Six Years Out From When This Beyaz / Safyral / YAZ / Yasmin / Gianvi / Ocella Drug Injury Litigation Started, Bayer Continues Its Slow-Going Pace (Posted by Tom Lamb at DrugInjuryWatch.com) To put into context the latest YAZ / Yasmin lawsui...
by Drug Injury Watch on Jun 22, 2015

Beyaz / Safyral / YAZ / Yasmin: These Drospirenone Containing Birth Control Pills Have A Higher Risk Of Blood Clot Side Effects Than Older Options

New Medical Journal Article Presents "Compelling Evidence" That These Newer Oral Contraceptives Are Associated With More Venous Thromboembolism Events (Posted by Tom Lamb at DrugInjuryWatch.com) Beyaz, Safyral, YAZ, and Yasmin are birth con...
by Drug Injury Watch on May 27, 2015

Testosterone Injections Or Shots Such As Depo-Testosterone Might Have Higher Risks Of Heart Attacks, Strokes, And Deaths

New Medical Research Suggests The Safety Of A Testosterone Drug Might Depend On Its Form: Injections / Shots; Creams / Gels; Skin Patches (Posted by Tom Lamb at DrugInjuryWatch.com) On March 3, 2015 an FDA Drug Safety Communication about testosterone...
by Drug Injury Watch on May 13, 2015

Does The Safety Of A Testosterone Drug Depend On Its Form: Injections / Shots; Creams / Gels; Skin Patches

New Medical Research About Testosterone Drugs Safety As Regards Heart Attacks, Strokes, And Deaths Which Might Be Caused By Their Use (Posted by Tom Lamb at DrugInjuryWatch.com) On March 3, 2015 an FDA Drug Safety Communication about testosterone pro...
by Drug Injury Watch on May 13, 2015

Diabetes Drugs Kombiglyze And Onglyza: Heart Failure Side Effect Seems To Be Valid, And FDA Notes There Is A Possible Increased Risk Of All-Cause Mortality

As Analysis Did Not Reveal Causes Of The Increase In Death Incidents, FDA Asks Its Advisory Committee To Discuss This Safety Issue At April 2015 Meeting (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________...
by Drug Injury Watch on Apr 13, 2015

YAZ / Yasmin Litigation Update For March 2015: According To Bayer's 2014 Annual Report, "Additional lawsuits are anticipated."

Bayer Claims It Settled About 300 Of These Cases While Another 1300 Lawsuits Were Filed From Mid-October 2014 To The End Of January 2015 (Posted by Tom Lamb at DrugInjuryWatch.com) For establishing a baseline as regards the current progress (or lack...
by Drug Injury Watch on Mar 16, 2015

Cardiovascular Safety Issues For Onglyza And Kombiglyze Will Be Discussed At April 2015 FDA Advisory Committee Meeting

These Two New AstraZeneca Diabetes Medications With Saxagliptin Are Part Of The Incretin Mimetic Class Of Drugs (Posted by Tom Lamb at DrugInjuryWatch.com) At an April 14, 2015 meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committe...
by Drug Injury Watch on Mar 9, 2015

Xolair Is Associated With Higher Than Expected Reporting Of Arterial Thrombotic Events Such As Strokes And Cardiovascular Deaths

While European Drug Regulators Have Been Concerned About This Aspect Of Xolair Safety, FDA Has No Warning About Arteriothrombotic Risks Of Xolair (Posted by Tom Lamb at DrugInjuryWatch.com) In September 2014 the FDA issued an update about its safety...
by Drug Injury Watch on Dec 26, 2014

December 2014 YAZ / Yasmin Litigation Update: Still Over 2000 DVT And/Or PE Cases Not Settled According To Bayer's Most Recent Financial Report

And New Blood Clot Side Effect Lawsuits, Including Some Involving The Lesser-Known Safyral And Beyaz DRSP Pills, Are Still Being Filed Against Bayer (Posted by Tom Lamb at DrugInjuryWatch.com) Bayer's latest update on the ongoing litigation concernin...
by Drug Injury Watch on Dec 12, 2014

Xolair Asthma Drug Associated With Higher Rate Of Heart Attacks, Pulmonary Hypertension, Blood Clots Causing PEs And/Or DVTs, And Brain Blood Vessel Problems

Since FDA Early Communication About An Ongoing Safety Review Of Xolair Was Issued In 2009, The Agency Has Been Examining Xolair Safety Profile But FDA Is Still Unsure If This Drug Is Safe Or Not (Posted by Tom Lamb at DrugInjuryWatch.com) In late Sep...
by Drug Injury Watch on Oct 1, 2014

Testosterone Drugs FDA Meeting In September 2014 Reveals That The Safety Of Products Like Axiron, AndroGel, And Testim Is Uncertain Or Unknown At Present Time

Key Advisory Panel Member Concedes It Is Medically Plausible That Testosterone Replacement Therapy Can Be Associated With Heart Attacks / Strokes Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) On September 17, 2014 members of the FDA's Bone...
by Drug Injury Watch on Sep 19, 2014

Summer 2014 Update YAZ / Yasmin / Ocella / Gianvi Litigation: Bayer Reports On Total Settlements And Number Of Pending Claims

Perhaps The Slow-Going Over Past Year Will Be Changed By Upcoming Mediations With Two Special Masters Appointed Recently By Judge Herndon (Posted by Tom Lamb at DrugInjuryWatch.com) In their Stockholders' Newsletter Financial Report as of June 30, 20...
by Drug Injury Watch on Sep 12, 2014

AndroGel / Axiron / Testim: Heart Attacks, Strokes, And Other Cardiovascular Problems Will Be Subject Of FDA Advisory Panel Meeting In September 2014

Health Canada Orders Label Change For Testosterone Drugs In July 2014: Must Warn About Increased Risks Of Side Effects Including Blood Clots, DVTs, PEs (Posted by Tom Lamb at DrugInjuryWatch.com) The safety issues concerning the popular testosterone...
by Drug Injury Watch on Jul 18, 2014


Trending Topics

Close